z-logo
Premium
Oral cobalamin (vitamin B 12 ) treatment. An update
Author(s) -
ANDRÈS E.,
DALIYOUCEF N.,
VOGEL T.,
SERRAJ K.,
ZIMMER J.
Publication year - 2009
Publication title -
international journal of laboratory hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.705
H-Index - 55
eISSN - 1751-553X
pISSN - 1751-5521
DOI - 10.1111/j.1751-553x.2008.01115.x
Subject(s) - cobalamin , malabsorption , pernicious anemia , medicine , vitamin b12 , gastroenterology , megaloblastic anemia , prospective cohort study , anemia , pediatrics
Summary The objective of this review was to evaluate oral cobalamin (vitamin B 12 ) therapy in adult and elderly patients, from the perspective of a hematologist. PubMed was systematically searched for English and French articles published from January 1990 to January 2007. Data from our working group, the ‘ Groupe d’étude des carences en vitamine B 12 des Hôpitaux Universitaires de Strasbourg ’, have also been included. Several prospective studies in well‐determined population ( n  = 4), prospective randomized studies ( n  = 3) and a systematic review by the Cochrane group ( n  = 1) provide evidence that oral cobalamin therapy may adequately treat cobalamin deficiency, particularly hematological abnormalities or manifestations. These studies suggest that at least 1000  μ g/day of oral cyanocobalmin are needed for pernicious anemia and a mean daily dose of 250  μ g for food‐cobalamin malabsorption. This present review confirms the previously reported efficacy of oral cobalamin treatment in adult and elderly patients.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here